Daclaxen (Daclatasvir) Tablets

Indicated for use in combination with other medicinal products for the treatment of chronic Hepatitis C (CHC) in adults:

• 🦠 Genotypes 1–4: Effective across multiple viral genotypes.
• 🏥 Liver Condition: Suitable for patients with compensated cirrhosis.
• 🛡️ Co-infection: Safe for patients co-infected with HIV.

Packaging: 60 mg film-coated tablets.

⚠️ ADMINISTRATION PROTOCOL (Combination Therapy Only):

• 💊 Dose: One tablet (60 mg) taken orally once daily.
• 🕒 Consistency: Take at the same time every day to maintain viral suppression.
• 🍲 With/Without Food: Can be taken with or without food. Swallow whole.
• 📅 Duration: Typically 12 weeks. Can be extended to 24 weeks for difficult-to-treat cases (e.g., decompensated cirrhosis).

• Monotherapy: Do not take alone; must be combined with Sofosbuvir.
• Hypersensitivity to the active substance.
• Pregnancy and breastfeeding.
• Co-administration with strong inducers of cytochrome P450 3A4 (e.g., St. John’s wort, rifampicin, carbamazepine, phenytoin).

When used with Sofosbuvir, the regimen is generally well-tolerated. Common side effects include:

• 🤯 Neurological: Headache, dizziness.
• 💤 General: Fatigue, lassitude.
• 🤢 Gastrointestinal: Nausea.
• ⚠️ Drug Interaction: Serious bradycardia may occur if taken with Amiodarone.